There are several noninvasive techniques for assessing the kinetics of tear film, but no comparative studies have been conducted to evaluate their efficacies. Our aim is to test and compare techniques based on high-speed videokeratoscopy (HSV), dynamic wavefront sensing (DWS), and lateral shearing interferometry (LSI). Algorithms are developed to estimate the tear film build-up time T(BLD), and the average tear film surface quality in the stable phase of the interblink interval TFSQ(Av). Moderate but significant correlations are found between T(BLD) measured with LSI and DWS based on vertical coma (Pearson's r(2)=0.34, p<0.01) and higher order rms (r(2)=0.31, p<0.01), as well as between TFSQ(Av) measured with LSI and HSV (r(2)=0.35, p<0.01), and between LSI and DWS based on the rms fit error (r(2)=0.40, p<0.01). No significant correlation is found between HSV and DWS. All three techniques estimate tear film build-up time to be below 2.5 sec, and they achieve a remarkably close median value of 0.7 sec. HSV appears to be the most precise method for measuring tear film surface quality. LSI appears to be the most sensitive method for analyzing tear film build-up.

Download full-text PDF

Source
http://dx.doi.org/10.1117/1.3431103DOI Listing

Publication Analysis

Top Keywords

tear film
16
lateral shearing
8
shearing interferometry
8
dynamic wavefront
8
wavefront sensing
8
high-speed videokeratoscopy
8
film surface
8
interferometry dynamic
4
sensing high-speed
4
videokeratoscopy noninvasive
4

Similar Publications

Perfluorohexyloctane ophthalmic solution (Miebo) and water-free cyclosporine ophthalmic solution 0.1% (Vevye) are recently approved treatments for dry eye disease (DED). Perfluorohexyloctane (PFHO) uses a novel approach to treat evaporative DED, whereas water-free cyclosporine (CsA 0.

View Article and Find Full Text PDF

Purpose: To visualize the behavior of perfluorohexyloctane (PFHO), an eye drop to treat dry eye disease (DED), on the surface of saline in vitro and on the human ocular surface using infrared emissivity.

Methods: Emissivity videos were used to measure the spreading and disappearance rates of PFHO on saline (with and without mucin for spreading rate) and layered over a 125 nm film of meibum on the surface of saline using a TearView camera. Ocular surface emissivity was videoed in a volunteer without DED before and after instillation of 1 drop of PFHO.

View Article and Find Full Text PDF

Scleral Contact Lens Benefits for Myopic Patients With Regular Corneas: A Prospective Randomized Study.

Eye Contact Lens

November 2024

Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China.

Objectives: To evaluate the impact of scleral contact lens (SL) wear on the visual quality and the ocular surface wettability in myopic patients with regular corneas.

Methods: This prospective, randomized, controlled study enrolled a total of 80 myopes with regular corneas. Subjects were randomly allocated to wear SL or rigid corneal lens (RCL) for 3 months.

View Article and Find Full Text PDF

Background: Overexpression of tear matrix metalloproteinases-9 (MMP-9) on the ocular surface tissues has been reported to result in ocular surface damage. MMP-9 levels in tears have been listed as one of many tools for confirming dry eye disease (DED).

Objective: This investigation aimed to compare MMP-9 levels and ocular surface parameters in diabetic patients with and without DED.

View Article and Find Full Text PDF

An update on emerging pharmacological treatments for meibomian gland dysfunction.

Expert Opin Pharmacother

January 2025

Eye Clinic, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.

Introduction: Meibomian Gland Dysfunction (MGD) represents the most common cause of dry eye disease (DED). Traditional treatments mainly rely on heating and liquifying the meibum to favor its expression. However, recent knowledge advances have led to the development of novel therapies specifically designed for patients with MGD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!